997 T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors

Document Type

Presentation

Publication Date

11-8-2022

Keywords

oregon; chiles

Abstract

Background Immune surveillance can eliminate developing cancers at the early stages of malignant transformation. The selective pressure that the immune system imposes on tumor cells, however, can “edit” tumors, yielding immune escape variants. Many tumors contain clones that cease to express antigenic proteins. Intra-tumoral antigenic heterogeneity is an important mechanism by which progressing tumors become refractory to standard immunotherapeutic interventions. This is particularly problematic for interventions that target a single antigen, such as adoptive T cell therapies and CAR T cells. Current immunotherapies in the clinic consist of strategies that mobilize the adaptive compartment of the immune system. The most common approaches include immune checkpoint blockade with antibodies, infusion of ex vivo educated or genetically modified tumor-specific T cells, and therapeutic anti-tumor vaccination. Moreover, a wave of agents that target tumor necrosis factor receptor (TNFR) superfamily members expressed by activated T cells, such as glucocorticoid induced TNF receptor (GITR), 4-1BB and OX40 are being further investigated. The role of neutrophils in tumor promotion versus tumor elimination is not well understood. The pro-tumorigenic role of neutrophils in chronic inflammation has been described. Higher neutrophil-to-lymphocyte ratios are associated with deleterious outcomes in patients receiving immune checkpoint blockade. Moreover, neutrophil effector mechanisms such as the formation of NETs can promote metastases and can shield tumors from effector T cell elimination. In other models, however, neutrophils and NETs can directly kill cancer. The role of neutrophils as potential effectors in the context of immunotherapies that target T cells remains incompletely defined. Methods We applied a combination therapy consisting of cyclophosphamide (CTX), CD4+ T cells specific for the melanoma antigen Trp1 (Trp1 cells), and an anti-OX40 agonist or anti-CTLA-4 antagonist antibodies to mice bearing advanced antigenically heterogeneous melanomas. Results Complete eradication of heterogenous melanomas was observed in mice treated with the combination therapy. Surprisingly, regressing tumors were heavily infiltrated with neutrophils with a distinct anti-tumorigenic phenotype and neutrophil depletion abrogated tumor eradication. Upon closer examination, we observed that inducible nitric oxide synthase expressed by neutrophils was necessary for heterogenous tumor elimination. In support of these findings, extensive neutrophil activation in biopsies of melanoma patients treated with immune checkpoint blockade. Moreover, our findings uncover a novel interplay between T cells mediating the initial anti-tumor immune response, and neutrophils mediating the destruction of tumor antigen loss variants.

Clinical Institute

Cancer

Department

Oncology

Department

Earle A. Chiles Research Institute

Comments

Presented at the SITC Annual Meeting; November 8-12; Boston, MA Authors: Sadna Budhu1, David Redmond2, Jacob Ricca1, Billel Gasmi1, Mathieu Gigoux1, Cailian Liu1, Yanyun Li1, Czrina Cortez1, David Schroder1, Arshi Arora1, Travis Hollman1, Lukas Kraehenbuehl1, Hyejin Choi1, Sara Schad1, Isabell Schulze1, Rebekka Duhen3, Andrew Weinberg3, Andrew Chow1, Mikala Egeblad4, Katherine Panageas1, Gabrielle Rizzuto5, Olivier de Henau1, Aliya Holland1, Jean Albrengues4, Linda Hamadane1, David Ng4, Xue-Yan He4, Jedd Wolchok1, Taha Merghoub1 and Daniel Hirschhorn1

This document is currently not available here.

PSJH Full Text

Share

COinS